Holley Pharmaceuticals Loses Copyright Infringement Case
This article was originally published in PharmAsia News
Executive Summary
Chongqing Intermediate People's Court has declared Holley Pharmaceuticals (Chongqing) guilty of infringing on Chongqing Jianqiao Pharmaceutical Development's copyright. It ordered HolleyPharm to stop production of its Duo-Cotecxin (dihydroartemisinin) tablets immediately and destroy any drugs produced before the ruling, as well as pay Chongqing Jianqiao 1 yuan for economic losses. HolleyPharm has indicated it will appeal to Chongqing Higher People's Court but states that there will be little impact on its overseas drug production and sales even if the future ruling remains the same. According to the company, Duo-Cotecxin revenue in China makes up only 1 percent of its total income. (Click here for more - Chinese Language)
You may also be interested in...
Chongqing Jianqiao Sues HolleyPharm Again For Patent Infringement
Chongqing Jianqiao Pharmaceutical Development has again sued Holley Pharmaceuticals, alleging that the latter's Duo-Cotecxin (dihyhroartermisinin piperaquine) tablets infringe on its patented compound for piperaquine tablets. Chongqing Jianqiao demands that HolleyPharm stop production and sale of the product, pay RMB 1 for economic losses, as well as issue a public apology and pay for court expenses. HolleyPharm claims thatDuo-Cotecxin's components are totally different from those of Chongqing Jianqiao's piperaquine tablets and it will be fighting the suit. Meanwhile, HolleyPharm has appealed its previous patent infringement case (PharmAsia News, Jul. 28, 2008). Analysts observe that an unfavourable ruling will negatively impact the firm as it will have to stop producing and selling Duo-Cotecxin locally if it loses the two cases. (Click here for more - Chinese Language)
HolleyPharm Patent Infringement Lawsuit Takes Favorable Turn
The Patent Re-examination Board of the State Intellectual Property Office of the P.R.C. has given its verdict on the copyright infringement case of Holley Pharmaceuticals (Chongqing) against Chongqing Jianqiao Pharmaceutical Development's product (PharmAsia News, July 28, 2008). SIPO decided that Chongqing Jianqiao's dihydroartemisinin patent lacks creative innovation, thus has ruled in favor of HolleyPharm's subsidiary Beijing Holly-Cotec Pharmaceuticals application for declaring the patent invalid. The judgment will serve as evidence for HolleyPharm's copyright lawsuit appeal to Chongqing Higher People's Court. (Click here for more - Chinese Language)
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.